In yesterday’s Wall Street session, Mereo BioPharma Group plc (NASDAQ:MREO) shares traded at $1.26, up 6.78% from the previous session.
2 analysts cover Mereo BioPharma Group plc (NASDAQ:MREO), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $4.00, we find $4.50. Given the previous closing price of $1.18, this indicates a potential upside of 281.36 percent. MREO stock price is now 1.89% away from the 50-day moving average and 27.77% away from the 200-day moving average. The market capitalization of the company currently stands at $157.48M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $4.50 as their price target over the next twelve months.
With the price target of $4, Cantor Fitzgerald recently initiated with Overweight rating for Mereo BioPharma Group plc (NASDAQ: MREO).
There have been several recent changes in the stakes of large investors in MREO stock. A new stake in Mereo BioPharma Group plc shares was purchased by BOOTHBAY FUND MANAGEMENT, LLC during the first quarter worth $539,000. ACADIAN ASSET MANAGEMENT LLC invested $242,000 in shares of MREO during the first quarter. In the first quarter, WORTH VENTURE PARTNERS, LLC acquired a new stake in Mereo BioPharma Group plc valued at approximately $96,000. SEI INVESTMENTS CO acquired a new stake in MREO for approximately $74,000. PFG INVESTMENTS, LLC purchased a new stake in MREO valued at around $60,000 in the second quarter. In total, there are 69 active investors with 51.10% ownership of the company’s stock.
On Friday morning Mereo BioPharma Group plc (NASDAQ: MREO) stock kicked off with the opening price of $1.1800. During the past 12 months, Mereo BioPharma Group plc has had a low of $0.49 and a high of $1.52. The fifty day moving average price for MREO is $1.2389 and a two-hundred day moving average price translates $0.9875 for the stock.
The latest earnings results from Mereo BioPharma Group plc (NASDAQ: MREO) was released for Dec, 2022.
Mereo BioPharma Group plc(MREO) Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
